全文获取类型
收费全文 | 814681篇 |
免费 | 60784篇 |
国内免费 | 10211篇 |
学科分类
医药卫生 | 885676篇 |
出版年
2021年 | 11139篇 |
2020年 | 8064篇 |
2019年 | 9389篇 |
2018年 | 11973篇 |
2017年 | 9773篇 |
2016年 | 10329篇 |
2015年 | 12915篇 |
2014年 | 16832篇 |
2013年 | 21144篇 |
2012年 | 28901篇 |
2011年 | 30781篇 |
2010年 | 18584篇 |
2009年 | 16564篇 |
2008年 | 25957篇 |
2007年 | 27416篇 |
2006年 | 27614篇 |
2005年 | 26249篇 |
2004年 | 23738篇 |
2003年 | 22395篇 |
2002年 | 21407篇 |
2001年 | 38881篇 |
2000年 | 39611篇 |
1999年 | 33273篇 |
1998年 | 9840篇 |
1997年 | 8624篇 |
1996年 | 8095篇 |
1995年 | 8057篇 |
1994年 | 7330篇 |
1993年 | 6351篇 |
1992年 | 23914篇 |
1991年 | 23691篇 |
1990年 | 22953篇 |
1989年 | 22675篇 |
1988年 | 20532篇 |
1987年 | 19843篇 |
1986年 | 18839篇 |
1985年 | 17582篇 |
1984年 | 12811篇 |
1983年 | 10837篇 |
1979年 | 11550篇 |
1978年 | 8121篇 |
1977年 | 6813篇 |
1976年 | 6582篇 |
1975年 | 7256篇 |
1974年 | 8491篇 |
1973年 | 8132篇 |
1972年 | 7652篇 |
1971年 | 7124篇 |
1970年 | 6872篇 |
1969年 | 6298篇 |
排序方式: 共有10000条查询结果,搜索用时 237 毫秒
91.
92.
Sebastian P. Mondaca MD Dazhi Liu PharmD BCOP Jessica R. Flynn Sandy Badson Stefan Hamaway BS Mrinal M. Gounder MD Danny N. Khalil MD PhD Alexander E. Drilon MD Bob T. Li MD MPH Komal L. Jhaveri MD Alison M. Schram MD Katherine E. Kargus RN Mary Kate Kasler DNP MSN Natalie M. Blauvelt Neil H. Segal MD PhD Marinela Capanu PhD Margaret K. Callahan MD PhD David M. Hyman MD Maya Gambarin-Gelwan MD James J. Harding MD 《Cancer》2020,126(22):4967-4974
93.
Jie Qian Wei Nie Jun Lu Lele Zhang Yanwei Zhang Bo Zhang Shuyuan Wang Minjuan Hu Jianlin Xu Yuqing Lou Yu Dong Yanjie Niu Bo Yan Runbo Zhong Wei Zhang Tianqing Chu Hua Zhong Baohui Han 《International journal of cancer. Journal international du cancer》2020,146(11):3124-3133
This study aimed to compare the differences in characteristics and prognoses between Asian and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC). We studied 390 patients who received atezolizumab as part of the POPLAR or OAK trial, and analyzed the differences in baseline characteristics, outcomes and genetic mutations in blood samples between Asian and white patients. Overall survival (OS) was longer in Asian compared to white patients (median OS: 18.7 vs. 11.1 months; p = 0.005). Race was identified as an independent prognostic factor for OS (Asian vs. white: hazard ratio 0.647, 95% confidence interval 0.447–0.936, p = 0.021), together with performance status, histology, baseline sum of the longest tumor diameters (BLSLD) and number of metastatic sites. The two groups also differed in terms of characteristics including smoking history, BLSLD, epidermal growth factor receptor (EGFR) mutation frequency, programmed death-ligand 1 expression and blood-based tumor-mutation burden. Blood mutations of STK11, EGFR, KEAP1, POLE, GRM3, ATM and STAG2 were associated with treatment response, and TP53, KEAP1, APC, RB1, CREBBP, EPHA5 and STAG2 mutations were associated with OS. The blood-based mutation profiles differentiated between Asian and white patients, especially in relation to EGFR (23.8 vs. 8.5%), TP53 (30.2 vs. 46.9%) and STK11 (1.6 vs. 12.3%) mutations (all p < 0.05). The different clinicopathological features and mutation profiles in Asian and white patients may explain the superior outcome following atezolizumab treatment in Asian patients with NSCLC. The results of this study have important implications for further studies on racial disparities in relation to immunotherapy. 相似文献
94.
目的:探讨miR-26b参与原发性肝细胞肝癌(HCC)侵袭的机制。方法:在细胞培养液中培养人肝细胞系HL-7702和HCC细胞各系Hepb-3、HuH-7、MHCC97-L、MHCC97-H。实时荧光定量PCR法(qRT-PCR)检测miR-26b的表达水平;用miR-26b mimics、miR-26b inhibitors和Notch1-siRNA分别转染HCC细胞;MTT实验检测转染后HCC细胞的活力;采用Western blot检测Notch1受体蛋白表达水平的变化;Transwell小室测定不同处理后的HCC细胞的侵袭能力。结果:人正常肝细胞系HL-7702和HCC细胞系Hepb-3、HuH-7、MHCC97-L、MHCC97-H中的miR-26b相对表达含量随其侵袭和迁移能力的升高而依次下降;抑制miR-26b的表达,Notch1受体蛋白表达明显增高,而此时HCC细胞的侵袭性显著增强;相反,上调miR-26b的表达,Notch1受体蛋白表达明显降低,而HCC细胞侵袭性显著下降;miR-26b可能通过调控Notch1信号通路调节HCC细胞侵袭性。结论:miR-26b通过负调控Notch1信号通路抑制HCC细胞侵袭能力,为HCC侵袭的机制奠定了理论基础,miR-26b可能成为HCC治疗的新靶点。 相似文献
95.
96.
97.
随着腔镜技术的进一步发展以及微创理念应用于结直肠外科疾病的诊治中,结直肠相关疾病的诊治发生了翻天覆地的变化。由传统的经腹手术到腹腔镜手术、经自然腔道手术,再到经自然腔道取标本手术(NOSES),结直肠疾病的外科诊治在微创领域取得了巨大成果。NOSES技术是目前结直肠外科在微创领域前沿的手术方式之一,它通过经直肠、阴道取标本来避免了腹壁的辅助取标本切口,从而将结直肠外科手术进一步微创化。NOSES技术集传统腹腔镜手术的优势与现代微创外科的理念于一体,它在确保手术效果的基础上集中体现了微创、加速康复外科、功能外科、"无疤"等理念的特点。本文主要就国内外各中心开展NOSES技术在结直肠外科诊治开展中的相关经验、心得和体会进行综述。 相似文献
98.
徐璐思 《中国医院建筑与装备》2020,(3):40-43
与一般医疗建筑设计师的经历不太相同,王冠楠的从业经历可谓“一波三折”。2002年毕业于哈尔滨工业大学建筑学专业的王冠楠最初入职的是中国航天建筑设计研究院,主要从事航天科技保密项目的设计;2003年为了接触市场化的建筑,王冠楠进入建筑大师杨经文的工作室,主要从事住宅与科研办公类建筑的设计,并在此领域取得了一些荣誉,如:2005年的三环新城项目获得北京市优秀工程二等奖;2010年的中国气象局预测中心业务楼获得北京市优秀工程三等奖。2011年初,已小有所成的王冠楠为了寻求更大的突破,加入到以医疗建筑设计见长的中国中元国际工程有限公司(以下简称“中元”),从此踏上医疗建筑的设计之路。 相似文献
99.
100.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献